Literature DB >> 12162687

Cross-reactivity of cefotetan and ceftriaxone antibodies, associated with hemolytic anemia, with other: cephalosporins and penicillin.

Patricia A Arndt1, George Garratty.   

Abstract

Most drug-induced immune hemolytic anemias since the late 1980s have been caused by the second- and third-generation cephalosporins, cefotetan and ceftriaxone, respectively. Cross-reactivity of cefotetan and ceftriaxone antibodies with other cephalosporins or penicillin has been studied only minimally. We tested 7 serum samples previously identified to contain cefotetan antibodies and one serum sample previously identified to contain ceftriaxone antibodies against 9 other cephalosporins, penicillin, and 7-aminocephalosporanic acid in the presence of RBCs and also used hapten inhibition to indicate cross-reactivity. Serum samples containing cefotetan antibodies showed some cross-reactivity with cephalothin and cefoxitin (and to a much lesser extent with penicillin and ceftazidime). The ceftriaxone antibodies showed very weak cross-reactivity with cefotaxime, cefamandole, and cefoperazone. There was very little cross-reactivity between cefotetan antibodies and the drugs tested in the present study. We have no data to determine whether the in vitro data relate to in vivo reactivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162687     DOI: 10.1309/JFJE-VUKN-221T-G6EV

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Opposite effects of cefoperazone and ceftazidime on S‑ribosylhomocysteine lyase/autoinducer-2 quorum sensing and biofilm formation by an Escherichia coli clinical isolate.

Authors:  Hui-Qing Shi; Feng-Jun Sun; Jian-Hong Chen; Xiao-Lan Yong; Qian-Yi Ou; Wei Feng; Pei-Yuan Xia
Journal:  Mol Med Rep       Date:  2014-09-05       Impact factor: 2.952

Review 2.  The Clinical Pictures of Autoimmune Hemolytic Anemia.

Authors:  Charles H Packman
Journal:  Transfus Med Hemother       Date:  2015-09-11       Impact factor: 3.747

3.  Case Report: Haemolytic anaemia with ceftazidime use in a patient with cystic fibrosis.

Authors:  Jun Yong; Freddy Frost; Dilip Nazareth; Martin Walshaw
Journal:  F1000Res       Date:  2018-04-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.